Anti-EPHB2/ CAPB/ DRT monoclonal antibody
Anti-EPHB2/ CAPB/ DRT antibody for FACS & in-vivo assay
Go to EPHB2/EPHB2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T73756-Ab-1/ GM-Tg-hg-T73756-Ab-2 | Anti-Human EPHB2 monoclonal antibody | Human |
GM-Tg-rg-T73756-Ab-1/ GM-Tg-rg-T73756-Ab-2 | Anti-Rat EPHB2 monoclonal antibody | Rat |
GM-Tg-mg-T73756-Ab-1/ GM-Tg-mg-T73756-Ab-2 | Anti-Mouse EPHB2 monoclonal antibody | Mouse |
GM-Tg-cynog-T73756-Ab-1/ GM-Tg-cynog-T73756-Ab-2 | Anti-Cynomolgus/ Rhesus macaque EPHB2 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T73756-Ab-1/ GM-Tg-felg-T73756-Ab-2 | Anti-Feline EPHB2 monoclonal antibody | Feline |
GM-Tg-cang-T73756-Ab-1/ GM-Tg-cang-T73756-Ab-2 | Anti-Canine EPHB2 monoclonal antibody | Canine |
GM-Tg-bovg-T73756-Ab-1/ GM-Tg-bovg-T73756-Ab-2 | Anti-Bovine EPHB2 monoclonal antibody | Bovine |
GM-Tg-equg-T73756-Ab-1/ GM-Tg-equg-T73756-Ab-2 | Anti-Equine EPHB2 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T73756-Ab-1/ GM-Tg-hg-T73756-Ab-2; GM-Tg-rg-T73756-Ab-1/ GM-Tg-rg-T73756-Ab-2; GM-Tg-mg-T73756-Ab-1/ GM-Tg-mg-T73756-Ab-2; GM-Tg-cynog-T73756-Ab-1/ GM-Tg-cynog-T73756-Ab-2; GM-Tg-felg-T73756-Ab-1/ GM-Tg-felg-T73756-Ab-2; GM-Tg-cang-T73756-Ab-1/ GM-Tg-cang-T73756-Ab-2; GM-Tg-bovg-T73756-Ab-1/ GM-Tg-bovg-T73756-Ab-2; GM-Tg-equg-T73756-Ab-1/ GM-Tg-equg-T73756-Ab-2 |
Products Name | Anti-EPHB2 monoclonal antibody |
Format | mab |
Target Name | EPHB2 |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-EPHB2 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | Products Developing | Multi-species EPHB2/ CAPB/ DRT VLP (virus-like particle) (Products Developing) |
Target information
Target ID | GM-T73756 |
Target Name | EPHB2 |
Gene ID | 2048,13844,313633,718570,487380,101095030,535137,100071661 |
Gene Symbol and Synonyms | BDPLT22,CAPB,Cek5,DRT,EK5,EPHB2,EPHT3,ERK,ETECK,Hek5,Nuk,PCBC,Prkm5,Qek5,RGD1564232,Sek3,Tyro5 |
Uniprot Accession | P29323 |
Uniprot Entry Name | EPHB2_HUMAN |
Protein Sub-location | Transmembrane Protein |
Category | Therapeutics Target |
Disease | Cancer |
Gene Ensembl | ENSG00000133216 |
Target Classification | Tumor-associated antigen (TAA) |
The target: EPHB2, gene name: EPHB2, also named as CAPB, DRT, EK5, EPHT3, ERK, Hek5, PCBC, Tyro5. This gene encodes a member of the Eph receptor family of receptor tyrosine kinase transmembrane glycoproteins. These receptors are composed of an N-terminal glycosylated ligand-binding domain, a transmembrane region and an intracellular kinase domain. They bind ligands called ephrins and are involved in diverse cellular processes including motility, division, and differentiation. A distinguishing characteristic of Eph-ephrin signaling is that both receptors and ligands are competent to transduce a signaling cascade, resulting in bidirectional signaling. This protein belongs to a subgroup of the Eph receptors called EphB. Proteins of this subgroup are distinguished from other members of the family by sequence homology and preferential binding affinity for membrane-bound ephrin-B ligands. Allelic variants are associated with prostate and brain cancer susceptibility. Alternative splicing results in multiple transcript variants. [provided by RefSeq, May 2015].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.